• Je něco špatně v tomto záznamu ?

The evolving landscape of biomarker testing for non-small cell lung cancer in Europe

KM. Kerr, F. Bibeau, E. Thunnissen, J. Botling, A. Ryška, J. Wolf, K. Öhrling, P. Burdon, U. Malapelle, R. Büttner

. 2021 ; 154 (-) : 161-175. [pub] 20210222

Jazyk angličtina Země Irsko

Typ dokumentu časopisecké články, práce podpořená grantem, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc21018939

The discovery of oncogenic driver mutations rendering non-small cell lung cancer (NSCLC) targetable by small-molecule inhibitors, and the development of immunotherapies, have revolutionised NSCLC treatment. Today, instead of non-selective chemotherapies, all patients with advanced NSCLC eligible for treatment (and increasing numbers with earlier, less extensive disease) require fast and comprehensive screening of biomarkers for first-line patient selection for targeted therapy, chemotherapy, or immunotherapy (with or without chemotherapy). To avoid unnecessary re-biopsies, biomarker screening before first-line treatment should also include markers that are actionable from second-line onwards; PD-L1 expression testing is also mandatory before initiating treatment. Population differences exist in the frequency of oncogenic driver mutations: EGFR mutations are more frequent in Asia than Europe, whereas the converse is true for KRAS mutations. In addition to approved first-line therapies, a number of emerging therapies are being investigated in clinical trials. Guidelines for biomarker testing vary by country, with the number of actionable targets and the requirement for extensive molecular screening strategies expected to increase. To meet diagnostic demands, rapid screening technologies for single-driver mutations have been implemented. Improvements in DNA- and RNA-based next-generation sequencing technologies enable analysis of a group of genes in one assay; however, turnaround times remain relatively long. Consequently, rapid screening technologies are being implemented alongside next-generation sequencing. Further challenges in the evolving landscape of biomarker testing in NSCLC are actionable primary and secondary resistance mechanisms to targeted therapies. Therefore, comprehensive testing on re-biopsies, collected at the time of disease progression, in combination with testing of circulating tumour DNA may provide important information to guide second- or third-line therapies. Furthermore, longitudinal biomarker testing can provide insights into tumour evolution and heterogeneity during the course of the disease. We summarise best practice strategies for Europe in the changing landscape of biomarker testing at diagnosis and during treatment.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21018939
003      
CZ-PrNML
005      
20210830100520.0
007      
ta
008      
210728s2021 ie f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.lungcan.2021.02.026 $2 doi
035    __
$a (PubMed)33690091
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ie
100    1_
$a Kerr, Keith M $u Department of Pathology, Aberdeen University Medical School and Aberdeen Royal Infirmary, Aberdeen, United Kingdom. Electronic address: k.kerr@abdn.ac.uk
245    14
$a The evolving landscape of biomarker testing for non-small cell lung cancer in Europe / $c KM. Kerr, F. Bibeau, E. Thunnissen, J. Botling, A. Ryška, J. Wolf, K. Öhrling, P. Burdon, U. Malapelle, R. Büttner
520    9_
$a The discovery of oncogenic driver mutations rendering non-small cell lung cancer (NSCLC) targetable by small-molecule inhibitors, and the development of immunotherapies, have revolutionised NSCLC treatment. Today, instead of non-selective chemotherapies, all patients with advanced NSCLC eligible for treatment (and increasing numbers with earlier, less extensive disease) require fast and comprehensive screening of biomarkers for first-line patient selection for targeted therapy, chemotherapy, or immunotherapy (with or without chemotherapy). To avoid unnecessary re-biopsies, biomarker screening before first-line treatment should also include markers that are actionable from second-line onwards; PD-L1 expression testing is also mandatory before initiating treatment. Population differences exist in the frequency of oncogenic driver mutations: EGFR mutations are more frequent in Asia than Europe, whereas the converse is true for KRAS mutations. In addition to approved first-line therapies, a number of emerging therapies are being investigated in clinical trials. Guidelines for biomarker testing vary by country, with the number of actionable targets and the requirement for extensive molecular screening strategies expected to increase. To meet diagnostic demands, rapid screening technologies for single-driver mutations have been implemented. Improvements in DNA- and RNA-based next-generation sequencing technologies enable analysis of a group of genes in one assay; however, turnaround times remain relatively long. Consequently, rapid screening technologies are being implemented alongside next-generation sequencing. Further challenges in the evolving landscape of biomarker testing in NSCLC are actionable primary and secondary resistance mechanisms to targeted therapies. Therefore, comprehensive testing on re-biopsies, collected at the time of disease progression, in combination with testing of circulating tumour DNA may provide important information to guide second- or third-line therapies. Furthermore, longitudinal biomarker testing can provide insights into tumour evolution and heterogeneity during the course of the disease. We summarise best practice strategies for Europe in the changing landscape of biomarker testing at diagnosis and during treatment.
650    _2
$a nádorové biomarkery $x genetika $7 D014408
650    12
$a nemalobuněčný karcinom plic $x diagnóza $x genetika $7 D002289
650    _2
$a lidé $7 D006801
650    12
$a nádory plic $x diagnóza $x genetika $7 D008175
650    _2
$a mutace $7 D009154
651    _2
$a Asie $7 D001208
651    _2
$a Evropa $7 D005060
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a přehledy $7 D016454
700    1_
$a Bibeau, Frédéric $u Department of Pathology, Caen University Hospital, Caen, Normandy University, France. Electronic address: Frederic.Bibeau@icm.unicancer.fr
700    1_
$a Thunnissen, Erik $u VU University Medical Center, Amsterdam, the Netherlands. Electronic address: e.thunnissen@amsterdamumc.nl
700    1_
$a Botling, Johan $u Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden. Electronic address: johan.botling@igp.uu.se
700    1_
$a Ryška, Aleš $u Department of Pathology, Charles University Medical Faculty Hospital, Hradec Kralove, Czech Republic. Electronic address: ryskaale@gmail.com
700    1_
$a Wolf, Jürgen $u University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany. Electronic address: juergen.wolf@uk-koeln.de
700    1_
$a Öhrling, Katarina $u Amgen (Europe) GmbH, Rotkreuz, Switzerland. Electronic address: kohrling@amgen.com
700    1_
$a Burdon, Peter $u Amgen (Europe) GmbH, Rotkreuz, Switzerland. Electronic address: peter.burdon@gmail.com
700    1_
$a Malapelle, Umberto $u Department of Public Health, University of Naples Federico II, 80131, Naples, Italy. Electronic address: umberto.malapelle@unina.it
700    1_
$a Büttner, Reinhard $u University of Cologne, Cologne Institute of Pathology, Cologne, Germany. Electronic address: reinhard.buettner@uk-koeln.de
773    0_
$w MED00003160 $t Lung cancer (Amsterdam, Netherlands) $x 1872-8332 $g Roč. 154, č. - (2021), s. 161-175
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33690091 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830100520 $b ABA008
999    __
$a ok $b bmc $g 1689893 $s 1139385
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 154 $c - $d 161-175 $e 20210222 $i 1872-8332 $m Lung cancer $n Lung Cancer $x MED00003160
LZP    __
$a Pubmed-20210728

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace